This week in therapeutics




Licensing status

Publication and contact information

Infectious disease


Mycobacterium tuberculosis long-chain fatty acid-CoA ligase (fadD32)

In vitro and mouse studies identified fadD32 inhibitors that could help treat tuberculosis. 4,6-Diaryl-5,7-dimethyl coumarin derivatives potently and selectively killed M. tuberculosis strains at submicromolar concentrations by inhibiting fadD32, a component of the mycolic acid biosynthesis pathway. In mice infected with M. tuberculosis, intraperitoneal administration of the most potent coumarin derivative cleared bacterial burden from the lungs as effectively as isoniazid. Next steps could include testing the new compounds in additional preclinical models.
Isoniazid is a generic tuberculosis therapeutic.

SciBX 6(29); doi:10.1038/scibx.2013.764
Published online Aug. 1, 2013

Patent and licensing status unavailable

Stanley, S.A. et al. Proc. Natl. Acad. Sci. USA; published online June 24, 2013;
Contact: Deborah T. Hung, Broad Institute of MIT and Harvard, Cambridge, Mass.